Zobrazeno 1 - 10
of 629
pro vyhledávání: '"Richard A Finn"'
Autor:
Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith Bliss, Katherine Pogue-Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, Lisa Swaim, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2
Externí odkaz:
https://doaj.org/article/89451dd2a5dd43c39359872a65b6f791
Autor:
Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, Valeriy Breder
Publikováno v:
Liver Cancer (2024)
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) vs sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpo
Externí odkaz:
https://doaj.org/article/d51ee563349d44e9ad5aa1c2a8eccf42
Autor:
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Publikováno v:
Liver Cancer (2024)
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR
Externí odkaz:
https://doaj.org/article/d6ae54a6e78a47678e598fa918d4b74a
Autor:
Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Publikováno v:
Liver Cancer (2024)
Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib as first-line (1L) treatment in adult patients with unresectable hepatocellular carcinoma (HCC) that met its primar
Externí odkaz:
https://doaj.org/article/1bff88f17a9a48489c63b55f5e686340
Autor:
David J Pinato, Kerigo Ndirangu, Richard S Finn, Zahra Ramji, Peter Galle, Catherine Ruth Mitchell, Gabrielle Sophie Redhead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Increased understanding of how the immune system regulates tumor growth has innovated the use of immunotherapeutics to treat various cancers. The impact of such therapies, including programmed cell death protein 1 (PD-1)/programmed death-l
Externí odkaz:
https://doaj.org/article/98e52ac30ac14b1e9804c53370c436f6
Autor:
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Publikováno v:
Liver Cancer (2023)
Background: Treatment with lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh
Externí odkaz:
https://doaj.org/article/9b3dbb00ba7849bcbc864150e49a693b
Autor:
Anand V. Kulkarni, Harshvardhan Tevethia, Karan Kumar, Madhumita Premkumar, Mark D. Muttaiah, Atsushi Hiraoka, Takeshi Hatanaka, Toshifumi Tada, Takashi Kumada, Satoru Kakizaki, Arndt Vogel, Richard S. Finn, Padaki Nagaraja Rao, Anjana Pillai, Duvvur Nageshwar Reddy, Amit G. Singal
Publikováno v:
EClinicalMedicine, Vol 63, Iss , Pp 102179- (2023)
Summary: Background: Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness and safety in other populations, including those with Child-Turc
Externí odkaz:
https://doaj.org/article/ea732d774da342e591c1f6808e94fa44
Autor:
Hope S. Rugo, Seock-Ah Im, Anil A. Joy, Yaroslav Shparyk, Janice M. Walshe, Bethany Sleckman, Sherene Loi, Kathy Puyana Theall, Sindy Kim, Xin Huang, Eustratios Bananis, Reshma Mahtani, Richard S. Finn, Véronique Diéras
Publikováno v:
Breast, Vol 66, Iss , Pp 324-331 (2022)
Background: Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients wit
Externí odkaz:
https://doaj.org/article/a722b0955acd4472b01e048a4c0096ba
Autor:
Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Data on real-world effectiveness of cyclin-dependent kinase 4/6 inhibitor combination therapy versus endocrine therapy alone are limited. The Flatiron Health Analytic Database was used to assess overall survival (OS) in patients with hormone
Externí odkaz:
https://doaj.org/article/532b070bf1404214b28d22f57d839c91
Autor:
Arndt Vogel, Richard S. Finn, Marie-Hélène Blanchet Zumofen, Carolina Heuser, Javier Sanchez Alvarez, Michael Leibfried, Catherine R. Mitchell, Sarah Batson, Gabrielle Redhead, Vincent E. Gaillard, Masatoshi Kudo
Publikováno v:
Liver Cancer (2023)
Background & aims: The objective of this systematic literature review (SLR) and network meta-analysis (NMA) is to compare randomised controlled trial evidence for atezolizumab-bevacizumab with globally relevant pharmacological comparators for first-l
Externí odkaz:
https://doaj.org/article/fe3269cb609e403787a57bf7cdbf8b92